16/09/2026 Sling therapeutics dosed the first patient in the Phase 3 trial of linsitinib for TED. Sling therapeutics dosed the first patient in the Phase 3 trial of linsitinib for TED. (Ref) First patient was dosed in Sling Therapeutics’ Phase 3, ORBIT/ NCT07753603 trial evaluating linsitinib (an insulin-like growth factor-1 receptor inhibitor) in adult with moderate to severe active thyroid eye disease (TED). The trial is expected to enroll ~ 130 participants, with the propo

31/08/2026 Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases Lilly announced 1-year Ph3b data on ixekizumab and tirzepatide used together in adults with psoriatic disease and obesity Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases (Ref) Eli Lilly and Company and Merida Biosciences announced a definitive agreement for Lilly to acquire Merida Biosciences, a biotechnology

30/06/2026 FDA granted priority review to Roche’s satralizumab as a treatment option for TED FDA granted priority review to Roche’s satralizumab as a treatment option for TED (Ref) Roche announced that the US FDA had accepted and granted priority review to a supplemental Biologics License Application (sBLA) for Enspryng® (satralizumab) for the treatment of thyroid eye disease (TED). The filing acceptance was based on results from the two randomized phase 3, SatraGO-1/ NCT0598

26/06/2026 SKYRIZI® received US FDA approval for pediatric psoriatic disease Viridian Therapeutics announced US FDA approval and commercial launch of Lumvoa™ for Thyroid Eye Disease SKYRIZI® received US FDA approval for pediatric psoriatic disease (Ref) AbbVie announced that the US FDA had approved SKYRIZI® (risankizumab-rzaa; IL-23 inhibitor) for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic ther

06/04/2026 Tenvie Therapeutics announced dosing of first subject in Phase 1 trial of TNV262 Amgen announced topline results from Phase 3 teprotumumab in active TED Tenvie Therapeutics announced dosing of first subject in Phase 1 trial of TNV262 ( Ref ) Tenvie Therapeutics announced the first subject dosed in a Phase 1 clinical study evaluating TNV262 (a fully CNS-penetrant small molecule inhibitor targeting NLRP3) for the treatment of cardiometabolic diseases, including obesi

02/04/2026 Immunovant announced Phase 3 results for batoclimab in thyroid eye disease Immunovant announced Phase 3 results for batoclimab in thyroid eye disease ( Ref ) Immunovant announced topline results from its two Phase 3 (GO) studies that evaluated batoclimab (an FcRn antagonist) for the treatment of adult patients with active, moderate-to-severe thyroid eye disease (TED) The studies failed to meet their primary endpoint of achieving ≥2mm proptosis responder rate at We